Alembic Pharma has been actively expanding its product portfolio and regulatory approvals, especially in the U.S. market and is well-positioned for multi-dimensional growth.
It operates a vertically integrated pharmaceutical business, allowing control over the entire value chain—from R&D to manufacturing and global marketing.
Key Segments:
Formulations: Branded generics and specialty drugs across therapeutic areas like cardiology, anti-infectives, diabetology, and gynecology.
APIs (Active Pharmaceutical Ingredients): Supplies to both internal and external clients.
Geographies:
India: Strong branded generics presence.
US: Focus on complex generics and injectables.
Ex-US: Rapidly growing markets in Asia, Africa, and Latin America.
Alembic exports to over 100 countries and is expanding its regulatory footprint. Strategic partnerships and contract manufacturing bolster international presence.
Risks & Challenges
Regulatory hurdles especially in the U.S. and EU.
Pricing pressure in generics, particularly in the U.S.
Competition from both Indian and global pharma players.
Raw Material Volatility - API supply chain risks.
It operates a vertically integrated pharmaceutical business, allowing control over the entire value chain—from R&D to manufacturing and global marketing.
Key Segments:
Formulations: Branded generics and specialty drugs across therapeutic areas like cardiology, anti-infectives, diabetology, and gynecology.
APIs (Active Pharmaceutical Ingredients): Supplies to both internal and external clients.
Geographies:
India: Strong branded generics presence.
US: Focus on complex generics and injectables.
Ex-US: Rapidly growing markets in Asia, Africa, and Latin America.
Alembic exports to over 100 countries and is expanding its regulatory footprint. Strategic partnerships and contract manufacturing bolster international presence.
Risks & Challenges
Regulatory hurdles especially in the U.S. and EU.
Pricing pressure in generics, particularly in the U.S.
Competition from both Indian and global pharma players.
Raw Material Volatility - API supply chain risks.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.